Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.

Albert QinDaoxiang WuYaning LiJingjing ZhangWei WangWeihong ShenJason LiaoSheena LinCynthia ChangHaoqi ChenJie CuiXia Su

Published in: British journal of clinical pharmacology (2024)

Our analyses have shown that patients with PV treated with ropeginterferon alfa-2b had an increased probability of achieving CHR and a molecular response with acceptable safety risks at the 250-350-500 μg titration dosing regimen. This study has provided the relevant data for the application of a biologics licence of ropeginterferon alfa-2b for PV treatment in China.

Keyphrases

replacement therapy
risk assessment
combination therapy
electronic health record
climate change
newly diagnosed